Verily Life Sciences LLC

Based in the US, Verily Life Sciences LLC is a health technology company focused on transforming healthcare through data-driven insights and advanced analytics, providing innovative solutions for better patient outcomes. Verily Life Sciences LLC operates as a health technology company, utilizing data analytics to improve healthcare delivery. Founded in 2015 in Dallas, US, the company has undergone strategic developments to enhance its offerings. The founders include Andrew Conrad, who has a notable history in healthcare innovation.

In March 2026, Verily Life Sciences LLC raised USD 300 million in venture funding led by Series X Capital, with participation from UCHealth and CU Healthcare Innovation Fund. As part of the transaction, Alphabet partially exited its stake in the company to become a minority shareholder. Verily offers a comprehensive Precision Health Platform designed to make healthcare data AI-ready, facilitating the integration and analysis of diverse health datasets. Central to their offerings is a data curation engine that harmonizes various data types, including electronic health records (EHR), laboratory results, unstructured physician notes, and genomic data.

This platform enables healthcare providers, researchers, and public health agencies to derive actionable insights that can enhance patient care and fuel medical discoveries. Key products include Workbench, a collaborative data analytics solution; Lightpath, which provides personalized care for chronic conditions; and Sightline, which assists in monitoring population health through wastewater-based epidemiology. The company serves a broad range of customers, including biotech and pharmaceutical companies, health systems, public health agencies, and employers, primarily in North America and Europe. Verily generates revenue through a combination of B2B partnerships, subscription models, and service agreements with healthcare organizations.

Their transactional structure largely revolves around licensing their data analytics platforms and providing tailored solutions to optimize healthcare delivery. For instance, health systems may subscribe to services such as Lightpath or Sightline, allowing them to implement AI-powered care models and public health monitoring systems. Pricing structures involve tiered subscription plans based on the scale of data usage and the specific features utilized, although exact figures are not disclosed. The company's flagship products, including the Workbench data platform, play a crucial role in driving revenue by providing advanced analytics capabilities to a diverse clientele in need of innovative healthcare solutions.

Verily Life Sciences LLC is focusing on launching new products designed to enhance its Precision Health Platform, although specific release dates are not mentioned. The company aims to expand its services into European markets and increase its presence in Asia by 2025. The company will use the March 2026 funding to accelerate its AI-native precision health platform strategy, enabling customers to harmonize healthcare data and deploy actionable intelligence across research and care workflows.